Acromegaly Complications Demand Individualized Treatment Beyond Hormone Control
A major review updates clinicians on managing acromegaly's wide-ranging complications, from heart disease to cancer risk.
Summary
Acromegaly, caused by excess growth hormone, does far more damage than abnormal growth alone. This review from leading endocrinologists at San Raffaele and Oregon Health & Science University synthesizes current evidence on the full spectrum of acromegaly complications — including heart and lung disease, metabolic disorders, bone problems, and elevated cancer risk. The authors emphasize that managing these comorbidities is just as critical as controlling growth hormone levels, and that treatment choices should be tailored to each patient's specific complication profile. Certain complications may even guide which medications are selected. The review aims to raise awareness among clinicians so that patients receive more comprehensive, individualized care that improves both quality of life and long-term survival.
Detailed Summary
Acromegaly is a rare but serious endocrine disorder caused by chronic excess of growth hormone, most often from a pituitary adenoma. While the hallmark features — enlarged hands, feet, and facial features — are well recognized, the systemic complications of acromegaly are responsible for much of its morbidity and mortality. This review, published in the Journal of Clinical Endocrinology and Metabolism, provides a comprehensive update on those complications and their management.
The authors, both internationally recognized pituitary disease experts, examine the pathophysiology, clinical presentation, and diagnostic approach to acromegaly's most clinically significant comorbidities. These include cardiorespiratory complications such as cardiomyopathy and sleep apnea, metabolic disturbances including insulin resistance and diabetes, skeletal consequences like vertebral fractures and arthropathy, and an elevated risk of certain malignancies.
A key theme of the review is that biochemical control of growth hormone and IGF-1 alone is insufficient. Comorbidities can persist or evolve independently, requiring active surveillance and targeted intervention. The authors also highlight that specific complications — particularly metabolic and cardiovascular ones — may influence the choice of pharmacologic therapy, since different somatostatin analogs, dopamine agonists, and GH receptor antagonists have varying metabolic profiles.
For clinicians, the practical implication is clear: acromegaly management must be multidisciplinary and individualized. Endocrinologists, cardiologists, pulmonologists, and oncologists may all need to be involved depending on the patient's complication burden.
This review is timely given evolving treatment options and growing recognition that survival gaps in acromegaly are largely driven by undertreated comorbidities. Raising awareness of these complications — and their interaction with therapy choices — is essential for improving patient outcomes. The primary caveat is that this summary is based on the abstract only, limiting insight into specific data and recommendations presented in the full text.
Key Findings
- Cardiorespiratory, metabolic, bone, and oncologic complications are the most clinically impactful in acromegaly.
- Biochemical control of growth hormone alone is insufficient — comorbidities require independent surveillance and treatment.
- Specific complications may drive pharmacologic choices, as different acromegaly drugs carry distinct metabolic profiles.
- Individualized, multidisciplinary management is essential to improve quality of life and survival in acromegaly.
- Undertreated comorbidities are a primary driver of the excess mortality seen in acromegaly patients.
Methodology
This is a narrative review article published in JCEM, synthesizing current literature on acromegaly comorbidities. The authors evaluated evidence on pathophysiology, diagnosis, clinical presentation, and treatment impact across multiple organ systems. No primary data were collected; conclusions are based on synthesis of existing research.
Study Limitations
This summary is based on the abstract only, as the full text is not open access, limiting access to specific data, recommendations, and referenced studies. As a narrative review, it is subject to selection bias in the literature chosen for inclusion. The review does not appear to include formal meta-analytic methodology or quality-of-evidence grading based on available information.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.